Foundayo FDA approval was officially announced today, marking a transformative moment for millions of Americans living with obesity. Eli Lilly and Company (NYSE: LLY) confirmed that the U.S. Food and Drug Administration (FDA) has cleared Foundayo™ (orforglipron), the first and only non-peptide oral GLP-1 receptor agonist for chronic weight management.
Unlike previous oral GLP-1 treatments that require strict fasting and water limitations, the Foundayo FDA approval introduces a medication that can be taken at any time of day, with or without food. This flexibility is expected to significantly improve patient adherence and accessibility in the rapidly evolving obesity care market.
The Significance of the Foundayo FDA Approval for Patients
The Foundayo FDA approval is rooted in the successful results of the ATTAIN-1 and ATTAIN-2 Phase 3 clinical trials. In these studies, participants taking the highest dose of orforglipron lost an average of 27.3 pounds (12.4% of their body weight) over 72 weeks, compared to just 2.2 pounds in the placebo group.
People living with obesity need treatment options that meet them where they are,
With the Foundayo FDA approval, we finally have an oral option that addresses both clinical efficacy and the practical daily challenges patients face.
Deborah Horn
Read More Eli Lilly’s Oral Weight-Loss Drug Orforglipron Shows Promising Results in Phase 3 Trial
Foundayo FDA Approval: Pricing and Availability
Lilly has moved quickly following the Foundayo FDA approval to ensure the medication reaches patients without delay. Key details regarding its launch include:
- Launch Date: Shipping is scheduled to begin on April 6, 2026.
- Distribution: Available via the LillyDirect® digital pharmacy and retail pharmacies nationwide.
- Cost: Eligible patients with commercial insurance may pay as little as $25 per month. For those without coverage, self-pay options start at $149 per month for the starting dose.
Comparing Foundayo to Existing GLP-1 Therapies
Before the Foundayo FDA approval, patients seeking GLP-1 therapy were largely limited to weekly injections or oral options with complex dosing requirements. Orforglipron is a small-molecule, non-peptide drug, meaning it is not broken down by stomach acid as easily as peptide-based drugs like semaglutide. This chemical structure is what allows Foundayo to be taken without the typical 30-minute fasting window.
MSD Oncology Pipeline Advances With First Phase 3 Data for Intismeran Autogene Plus KEYTRUDA and Sacituzumab Tirumotecan
The Merck oncology pipeline will present first-time Phase 3 results for intismeran autogene plus KEYTRUDA, sacituzumab tirumotecan and KEYTRUDA monotherapy in Madrid from Oct. 23-27, […]
Regeneron Libtayo Dosing Update: CHMP Recommends EU Approval of Every-Six-Week Cemiplimab Regimen Across All Cancer Types
Regeneron says the CHMP has recommended EU approval of an alternative Libtayo dosing schedule: 700 mg every six weeks after an initial 12-week regimen of […]
Lilly Omvoh (mirikizumab-mrkz) Delivers Comprehensive Disease Control in Ulcerative Colitis and Deep Remission in Crohn’s Disease at One Year
New post-hoc analyses from Eli Lilly show Lilly Omvoh (mirikizumab-mrkz) helped 27.7% of ulcerative colitis patients reach comprehensive disease control and 20.4% of Crohn’s disease […]
Safety and Regulatory Milestones
The Foundayo FDA approval also sets a regulatory record. The drug was cleared under the FDA’s new Commissioner’s National Priority Voucher (CNPV) program, resulting in one of the fastest approvals for a new molecular entity in over two decades.
According to the official FDA Press Announcement, the agency prioritized the review due to the high national priority of treating obesity-related comorbidities such as hypertension and cardiovascular disease. Like other medications in its class, Foundayo includes warnings regarding gastrointestinal side effects and thyroid C-cell tumors.
